- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00515684
Corneal Thinning During Topical Bevacizumab Therapy
April 29, 2015 updated by: Yonsei University
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- clinical diagnosis of corneal neovascularization
- must be able to apply eyedrop
Exclusion Criteria:
- have active keratitis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sang Woo Kim, M.D., Severance hospital, Seoul , Korea
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
December 1, 2008
Study Completion (Actual)
December 1, 2008
Study Registration Dates
First Submitted
August 13, 2007
First Submitted That Met QC Criteria
August 13, 2007
First Posted (Estimate)
August 14, 2007
Study Record Updates
Last Update Posted (Estimate)
May 1, 2015
Last Update Submitted That Met QC Criteria
April 29, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Corneal Diseases
- Metaplasia
- Neovascularization, Pathologic
- Corneal Neovascularization
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- 4-2006-0234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corneal Neovascularization
-
Reza Dana, MDUnited States Department of Defense; New York Presbyterian Hospital; Bascom Palmer...CompletedCorneal Neovascularization | Corneal Graft FailureUnited States
-
Reza Dana, MDCompletedCorneal Neovascularization | Corneal Graft FailureUnited States
-
Medical University of ViennaCompletedKeratoconus | Corneal NeovascularisationAustria
-
University of NottinghamUnknownCorneal Neovascularisation
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRecruitingCorneal NeovascularizationChina
-
Asociación para Evitar la Ceguera en MéxicoNational Council of Science and Technology, Mexico; Universidad Nacional Autonoma...CompletedCorneal NeovascularizationMexico
-
Chengdu Kanghong Biotech Co., Ltd.UnknownCorneal NeovascularizationChina
-
Chonnam National University HospitalCompletedCorneal Neovascularization
-
Massachusetts Eye and Ear InfirmaryCompletedCorneal NeovascularizationUnited States
-
Guangzhou HuiBoRui Biological Pharmaceutical Technology...ParexelUnknownCorneal NeovascularizationUnited States
Clinical Trials on bevacizumab (Avastin)
-
Hoffmann-La RocheCompletedGlioblastoma MultiformeSwitzerland, France, United Kingdom, Denmark
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Children's Hospital Los AngelesTemporarily not availableRetinopathy of PrematurityUnited States
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumTerminated
-
Northwell HealthFeinstein Institute for Medical Research; Hofstra North ShoreSuspendedVestibular SchwannomaUnited States
-
University of Southern CaliforniaCompletedDiabetic Retinopathy | Retinal DetachmentUnited States
-
mAbxience Research S.L.CompletedHealthy VolunteersUnited Kingdom
-
Universidad Autonoma de San Luis PotosíUnknownRetinopathy of PrematurityMexico
-
Massachusetts General HospitalCompletedRecurrent Respiratory PapillomatosisUnited States
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States